Vital Biosciences introduces revolutionary point-of-care lab testing platform & raises $48 million

Vital Biosciences recently introduced VitalOne, their revolutionary blood testing technology on plenary stage at the American Association of Clinical Chemistry (AACC) Annual Meeting and announced total funding of $48 million. The innovative solution reimagines point-of-care testing through VitalOne to create a world where patients will not need to take additional time off from work, travel between their primary care doctor and a lab, or wait for days to discuss their results with their healthcare provider.

Vital Biosciences is an alumnus of the BDSP™ and CAAP® programs.

Learn more
Previous
Previous

Vive Crop Protection selected for inaugural cohort of Canada’s Global Hypergrowth Project

Next
Next

Rostrum Medical announces the publication of initial validation results of its novel VQm® System